Cisco reports upbeat annual guidance after Q4 results top estimates

Investing.com
Updated
Mitrade
coverImg
Source: Shutterstock

Investing.com -- Cisco reported Wednesday upbeat guidance following fiscal fourth-quarter results that topped Wall Street estimates. 

Cisco Systems Inc (NASDAQ:CSCO) was flat in recent afterhours trading following the report.

Cisco announced Q3 adjusted EPS $0.91 on revenue of $13.8 billion. Analysts polled by Investing.com anticipated EPS of $0.87 on revenue of $13.78B.

Looking to fiscal Q1, the company expects adjusted EPS of $0.91 on revenue of $13.8B. That compared with estimates for EPS of $0.87 and revenue of $13.7B.

The company sees 2025 full-year adjusted earnings per share of $3.60 to $3.66 on revenue in a range of $55.3B to $56.3B. 

* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
India’s economy is tumbling, and it might take whole world down with itIndia’s economy is spiraling. The rupee is sinking like a stone, dragging with it a mix of trade deficits, shrinking capital inflows, and uncertainty. The country’s economy has quickly become so important that if it plummets, the global economy will be at stake.
Author  Cryptopolitan
10 hours ago
India’s economy is spiraling. The rupee is sinking like a stone, dragging with it a mix of trade deficits, shrinking capital inflows, and uncertainty. The country’s economy has quickly become so important that if it plummets, the global economy will be at stake.
placeholder
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.
Author  The Motley Fool
10 hours ago
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.
placeholder
Novo Nordisk Sees Retail Buying Despite Wall Street CutsShares of leading weight-loss drugmaker Novo Nordisk (NVO.US) plunged after disappointing results from its latest weight-loss drug trial. Despite analysts slashing their price targets, retail investors flooded into the stock with massive buy-the-dip activity.
Author  Mitrade
15 hours ago
Shares of leading weight-loss drugmaker Novo Nordisk (NVO.US) plunged after disappointing results from its latest weight-loss drug trial. Despite analysts slashing their price targets, retail investors flooded into the stock with massive buy-the-dip activity.
placeholder
The Year of Concentration, Crypto, ChinaWhy 2024 was such a good year for investors, and the concerns they have about valuations and market concentration as they look ahead to 2025.
Author  The Motley Fool
17 hours ago
Why 2024 was such a good year for investors, and the concerns they have about valuations and market concentration as they look ahead to 2025.
placeholder
Prediction: This Energy Stock Will Deliver Substantial Market-Beating ReturnsExplore the exciting world of Chart Industries (NYSE: GTLS) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Author  The Motley Fool
17 hours ago
Explore the exciting world of Chart Industries (NYSE: GTLS) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!